HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ChromaDex Ordered To Pay Elysium’s Attorney Fees

Judge Says ‘Never Any Serious Question’ ChromaDex’s Patent Claims Were Invalid

Executive Summary

“So lacking in substance that it ‘stands out’ from the dozens of [patent infringement] challenges I have encountered as a judge in the last five years,” says Colm Connolly, Delaware district chief judge. His ruling doesn’t end the firms’ litigation as related cases continue in federal courts in California and New York.

You may also be interested in...



ChromaDex Invests In Tru Niagen TV Ads As Study Results Spur Word-Of-Mouth Promotion

Firm emphasizes TV advertising spending and Walmart-related commercial launching in March in its earnings briefing. “We could go much broader than just sort of a male fitness sports-related cohort. We think it's a much broader-based market than that,” says CEO Robert Fried.

Split Decision In Breach-of-Contract Battle Of Litigation War Between ChromaDex, Elysium

California federal court jury found both breached contracts: Elysium failed to pay for nicotinamide riboside and pterostilbene it ordered and received, while ChromaDex violated pricing provision in supply agreement.

Biotech Industry Fears Fallout From Supreme Court’s Myriad Ruling

Supreme Court unanimously holds that DNA isolated from the human body cannot be patented but cDNA, which is created in a laboratory, can be; says Myriad “did not create anything.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel